Alzheimer disease, familial, type 3
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The reported APP-D694N iPSC line may be used to model and study human AD pathology in vitro.
|
31004935 |
2019 |
Alzheimer disease, familial, type 3
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated how social interaction affected cognitive function and AD pathology in APP/PS1 (amyloid precursor protein/presenilin-1) mice.
|
31034995 |
2019 |
Alzheimer disease, familial, type 3
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dermal fibroblasts were obtained from a 55 year old male Сaucasian familial Alzheimer's disease (AD) patient carrying heterozygous V717I mutation in the APP gene.
|
30851551 |
2019 |
Alzheimer disease, familial, type 3
|
0.100 |
Biomarker
|
disease |
BEFREE |
The increased level of APP Ser655 phosphorylation was observed in the brain of APP/PS1 mice and AD patients compared to controls.
|
31287605 |
2019 |
Alzheimer disease, familial, type 3
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These experiments indicate that Se and Zn have a protective effect on AD pathology that a possible mechanism is inhibiting the activity of γ-secretase to decreasing Aβ<sub>1-40</sub> production further influencing the APP processing.
|
29081063 |
2018 |
Alzheimer disease, familial, type 3
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tetraspanin 3 (Tspan3), which is highly expressed in the murine brain and elevated in brains of Alzheimer´s disease (AD) patients, was identified and confirmed to bind ADAM10 by co-immunoprecipitation experiments in mammalian cells in complex with APP and the γ-secretase protease presenilin.
|
27818272 |
2017 |
Alzheimer disease, familial, type 3
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, the results are suggesting that treatment of APP/E4/Abca1+/- mice with LXR agonist T0 ameliorates APOE4-induced AD-like pathology and therefore targeting the LXR-ABCA1-APOE regulatory axis could be effective as a potential therapeutic approach in AD patients, carriers of APOEε4.
|
28241068 |
2017 |
Alzheimer disease, familial, type 3
|
0.100 |
Biomarker
|
disease |
BEFREE |
PICALM might play an important role in AD pathology through participating in altering synaptic vesicle cycling or APP endocytosis.
|
20951388 |
2011 |
Alzheimer disease, familial, type 3
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three copies of APP are associated with AD pathology in Down's syndrome and in EOAD, suggesting that overexpression of APP may be a risk factor for LOAD.
|
17427190 |
2007 |
Alzheimer disease, familial, type 3
|
0.100 |
Biomarker
|
disease |
BEFREE |
The gene for amyloid precursor protein (APP), known to be involved in AD pathology, resides on chromosome 21 along with the gene for Cu/Zn superoxide dismutase (SOD1), a key enzyme in the metabolism of oxygen free radicals.
|
15016076 |
2004 |
Alzheimer disease, familial, type 3
|
0.100 |
Biomarker
|
disease |
BEFREE |
High cholesterol affects platelet APP processing in controls and in AD patients.
|
12885570 |
2003 |
Alzheimer disease, familial, type 3
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two human genes known to be involved in AD pathology are the amyloid precursor protein (APP) and the E4 isoform of apolipoprotein E (apoE4).
|
8744398 |
1996 |